Logo image of ALVO

ALVOTECH SA (ALVO) Stock Price, Quote, News and Overview

NASDAQ:ALVO - Nasdaq - LU2458332611 - Common Stock - Currency: USD

7.94  -0.03 (-0.38%)

After market: 10.01 +2.07 (+26.07%)

ALVO Quote, Performance and Key Statistics

ALVOTECH SA

NASDAQ:ALVO (5/7/2025, 8:00:00 PM)

After market: 10.01 +2.07 (+26.07%)

7.94

-0.03 (-0.38%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week High14.65
52 Week Low7.35
Market Cap2.40B
Shares301.81M
Float107.95M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PE16.92
Earnings (Next)05-07 2025-05-07/amc
IPO11-09 2020-11-09


ALVO short term performance overview.The bars show the price performance of ALVO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

ALVO long term performance overview.The bars show the price performance of ALVO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40

The current stock price of ALVO is 7.94 USD. In the past month the price decreased by -1.49%. In the past year, price decreased by -40.61%.

ALVOTECH SA / ALVO Daily stock chart

ALVO Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 18.31 332.73B
AMGN AMGEN INC 13.29 148.31B
GILD GILEAD SCIENCES INC 12.78 123.13B
VRTX VERTEX PHARMACEUTICALS INC N/A 111.78B
REGN REGENERON PHARMACEUTICALS 12.66 60.56B
ARGX ARGENX SE - ADR 327.86 38.04B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 35.97B
ONC BEIGENE LTD-ADR N/A 25.03B
BNTX BIONTECH SE-ADR N/A 22.31B
NTRA NATERA INC N/A 21.77B
SMMT SUMMIT THERAPEUTICS INC N/A 18.04B
BIIB BIOGEN INC 7.41 17.17B

About ALVO

Company Profile

ALVO logo image Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focused on the development and manufacture of biosimilar medicines for patients globally. The company is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). The company has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.

Company Info

ALVOTECH SA

9, Rue De Bitbourg

Luxembourg LU

Employees: 1011

ALVO Company Website

ALVO Investor Relations

Phone: 35244224500

ALVOTECH SA / ALVO FAQ

What is the stock price of ALVOTECH SA today?

The current stock price of ALVO is 7.94 USD. The price decreased by -0.38% in the last trading session.


What is the ticker symbol for ALVOTECH SA stock?

The exchange symbol of ALVOTECH SA is ALVO and it is listed on the Nasdaq exchange.


On which exchange is ALVO stock listed?

ALVO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for ALVOTECH SA stock?

10 analysts have analysed ALVO and the average price target is 18.36 USD. This implies a price increase of 131.23% is expected in the next year compared to the current price of 7.94. Check the ALVOTECH SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is ALVOTECH SA worth?

ALVOTECH SA (ALVO) has a market capitalization of 2.40B USD. This makes ALVO a Mid Cap stock.


How many employees does ALVOTECH SA have?

ALVOTECH SA (ALVO) currently has 1011 employees.


What are the support and resistance levels for ALVOTECH SA (ALVO) stock?

ALVOTECH SA (ALVO) has a support level at 7.93 and a resistance level at 8.23. Check the full technical report for a detailed analysis of ALVO support and resistance levels.


Is ALVOTECH SA (ALVO) expected to grow?

The Revenue of ALVOTECH SA (ALVO) is expected to grow by 42.14% in the next year. Check the estimates tab for more information on the ALVO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy ALVOTECH SA (ALVO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does ALVOTECH SA (ALVO) stock pay dividends?

ALVO does not pay a dividend.


When does ALVOTECH SA (ALVO) report earnings?

ALVOTECH SA (ALVO) will report earnings on 2025-05-07, after the market close.


What is the Price/Earnings (PE) ratio of ALVOTECH SA (ALVO)?

ALVOTECH SA (ALVO) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.87).


What is the Short Interest ratio of ALVOTECH SA (ALVO) stock?

The outstanding short interest for ALVOTECH SA (ALVO) is 0.74% of its float. Check the ownership tab for more information on the ALVO short interest.


ALVO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

ALVO Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to ALVO. ALVO may be in some trouble as it scores bad on both profitability and health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

ALVO Financial Highlights

Over the last trailing twelve months ALVO reported a non-GAAP Earnings per Share(EPS) of -0.87. The EPS increased by 64.39% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -18.98%
ROE N/A
Debt/Equity N/A
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%0%
EPS 1Y (TTM)64.39%
Revenue 1Y (TTM)426.84%

ALVO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to ALVO. The Buy consensus is the average rating of analysts ratings from 10 analysts.

For the next year, analysts expect an EPS growth of 104.4% and a revenue growth 42.14% for ALVO


Ownership
Inst Owners5.83%
Ins Owners0.61%
Short Float %0.74%
Short Ratio6.07
Analysts
Analysts78
Price Target18.36 (131.23%)
EPS Next Y104.4%
Revenue Next Year42.14%